Mineralocorticoid Deficiency and Treatment in Congenital Adrenal Hyperplasia

Approximately 75%–80% of patients with Congenital Adrenal Hyperplasia (CAH) fail to synthesize sufficient mineralocorticoids to maintain salt and water balance. In most instances genotype can predict mineralocorticoid deficiency in CAH. Early recognition and replacement with 9-fludrocortisone and salt supplements will prevent development of potentially lethal salt losing crises. In infancy a relative state of aldosterone resistance exists and replacement dose of 9-fludrocortisone based on body surface area is higher during infancy compared to childhood and adults. Salt supplementation is generally not required after weaning is started. Regular monitoring of blood pressure and measurements of plasma electrolytes and renin are required to prevent complications of under or over dosage.

[1]  P. Murgatroyd,et al.  Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia , 2010, Clinical endocrinology.

[2]  M. Lombès,et al.  Physiological Partial Aldosterone Resistance in Human Newborns , 2009, Pediatric Research.

[3]  D. Cowley,et al.  The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency. , 2009, The Clinical biochemist. Reviews.

[4]  P. Hindmarsh.  Management of the child with congenital adrenal hyperplasia. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[5]  S. Hahner,et al.  Therapeutic management of adrenal insufficiency. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[6]  W. Sippell,et al.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency , 2007, Reviews in Endocrine and Metabolic Disorders.

[7]  H. Dörr,et al.  Obesity Among Children and Adolescents With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency , 2006, Pediatrics.

[8]  J. Popović,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2005, Journal for specialists in pediatric nursing : JSPN.

[9]  Jacques Simard,et al.  Molecular Biology of the 3-Hydroxysteroid Dehydrogenase/5-4 Isomerase Gene Family , 2005 .

[10]  D. Bourchier.  Plasma aldosterone levels in the 1st week of life in infants of less than 30 weeks gestation , 2005, European Journal of Pediatrics.

[11]  M. Dattani,et al.  Blood pressure in children and adolescents with congenital adrenal hyperplasia (21‐hydroxylase deficiency): a preliminary report , 2003, Clinical endocrinology.

[12]  W. Sippell,et al.  Management of Congenital Adrenal Hyperplasia: Results of the ESPE Questionnaire , 2002, Hormone Research in Paediatrics.

[13]  G. Chrousos,et al.  Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. , 2002, The Journal of clinical endocrinology and metabolism.

[14]  G. Chrousos,et al.  Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. , 2002, The Journal of clinical endocrinology and metabolism.

[15]  G. Chrousos,et al.  Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. , 2000, The New England journal of medicine.

[16]  A. Braun,et al.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  H. Bruining,et al.  Corticosteroid therapy in severe illness. , 1997, The New England journal of medicine.

[18]  J. Partanen,et al.  Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. , 1997, The Journal of clinical endocrinology and metabolism.

[19]  W. Oelkers.  Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure , 1996, Steroids.

[20]  M. New,et al.  Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. , 1995, Journal of Clinical Endocrinology and Metabolism.

[21]  H. Luthman,et al.  Mutational Spectrum of the Steroid 21-Hydroxylase Gene In Sweden: Implications for Genetic Diagnosis and Association With Disease Manifestation , 1994 .

[22]  M. Tusié-Luna,et al.  Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 1992, The Journal of clinical investigation.

[23]  M. Forest,et al.  Congenital adrenal hyperplasia due to point mutations in the type II 3β–hydroxysteroid dehydrogenase gene , 1992, Nature Genetics.

[24]  A. Aynsley-Green,et al.  The steroid hormonal milieu of the undisturbed human fetus and mother at 16-20 weeks gestation. , 1991, The Journal of clinical endocrinology and metabolism.

[25]  P. White,et al.  HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. , 1984 .

[26]  R. Levinsky,et al.  Congenital adrenal hyperplasia: Renin and steroid values during treatment , 1977, European Journal of Pediatrics.

[27]  N. Berglind,et al.  Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. , 2007, The Journal of clinical endocrinology and metabolism.

[28]  H. Dörr,et al.  Plasma Levels of Aldosterone, Corticosterone, 11-Deoxycorticosterone, Progesterone, 17-Hydroxyprogesterone, Cortisol, and Cortisone During Infancy and Childhood , 1980, Pediatric Research.